‍‍Douglas Bradshaw, Head of Business Development at TTP contributes:

“In 2026, biopharma will accelerate investment in technologies and platforms that enable scalable and cost-efficient manufacture, building on momentum such as the recent $40m series A for Cellular Origins. As therapy developers consolidate and pivot toward indications with broader patient populations, the limitations of current manufacturing models will become more pronounced. Innovation around process closure will be needed to address the high facility costs of manual, open processes and move towards parallel and higher-intensity manufacturing. At the same time, the sector will increasingly recognize that scalability extends beyond core processing steps, driving demand for automation and digitalization across QC [quality control] workflows and ancillary material supply chains. These pressures will catalyze a new wave of enabling technologies in 2026.”

Read the full article here.